Carterra Ultra™
Disruptive technology for the characterization of small molecules and fragments. With enhanced sensitivity, expanded thermal options, and advanced microfluidics, the Carterra Ultra™ platform is our most sensitive instrument for interrogating multiple proteins and off-target binding in parallel.
Receive your quote directly from the manufacturer.
The Carterra Ultra is a revolutionary HT-SPR platform that includes enhanced optics, thermal controls, and microfluidics to provide the most advanced high-throughput screening and characterization platform on the market. For the first time, investigators can test fragments and small-molecules as well as large on- and off-targets arrays.
Ultra enables the following automated workflows in a single unattended run:
- Ligand interactions with analytes as small as 100 Dalton
- Kinetics and affinity: Characterize up to 768 fragments/small molecules or 1152 mAbs
- Epitope binning: Interrogate up to 191×191 mAb/mAb pairwise interactions
- Quantitation: Measure concentration of up to 1152 mAbs
- Epitope mapping: Screen up to 96 mAbs against an array of up to 96 peptides
- Blocking / neutralization assays: 96-sample capacity
- General multiplexed applications: Array any combination of up to 192 ligands, mutants, target variants, controls, etc.
Fragment screening of massively parallel ligand arrays using the Carterra Ultra SPR platform
Fragment-based lead discovery (FBLD) demands technologies that can detect low-affinity interactions across vast chemical space, posing throughput and sensitivity challenges. Discover how high-throughput surface plasmon resonance (SPR) innovations dramatically expand ligand capacity, streamline hit-to-lead workflows, and enable simultaneous analysis of over 100 targets, accelerating decision-making in early-stage drug discovery.
Product Overview
Links
Featured products
Request Quote for All Products
Carterra LSA-XT
CarterraDisruptive Technology for Screening and Characterization. Enhanced sensitivity and fast data collection rate build upon unmatched capabilities in throughput and enable assays such as TPDs/PROTAC®s, kinase, cytokines, DELs, and protein:protein inhibitors.
